Proveca Ltd
Simon Bryson has extensive work experience in the pharmaceutical and healthcare industry. Simon is the CEO and Founder of Proveca Ltd since July 2010, where they have been involved in leading the company. Simon is also a Board Member and Scientific Advisor for the Paediatric Medicines Research Unit at Alder Hey Children's NHS Foundation Trust since January 2019. In addition, they serve as an Advisory Group Expert for conect4children from January 2022. Simon has been a member of the Board for Health and Life Sciences at Liverpool City Region Local Enterprise Partnership since June 2016. Previously, they worked as the Director/Owner of Auralis Ltd from January 2005 to May 2010, and as an Executive Director at PowderJect/Chiron Vaccines from June 2002 to November 2004. Simon began their career at GlaxoSmithKline, where they served as the Director of Biopharmaceutical Development QA from 1998 to 2002.
Simon Bryson has a strong educational background in the field of pharmaceutical sciences and biochemistry. Simon holds a Doctor of Philosophy (PhD) degree in Paediatric Pharmaceutics from the University of Brighton. Prior to that, they obtained a Bachelor of Science (BSc) degree in Biochemistry from Newcastle University. Simon also holds a Master of Science (MSc) degree in Pharmaceutical Sciences from the University of Brighton. Additionally, they have obtained the certification of FRSB CBiol from the Royal Society of Biology.
Proveca Ltd
Proveca Ltd is a pharmaceutical company specialising in identifying, researching and licensing off-patent medicines with unmet priority health care needs, with a focus on the paediatric market. By developing the necessary formulations and clinical data required to obtain a Paediatric Use Marketing Authorisation (PUMA) these drugs will benefit froma period of 10 years' market protection (8 years of data and market protection plus 2 further years of market protection). In addition, where appropriate, Orphan Drug status (Orphan Drug) will be sought which affords a period of 10 years' market exclusivity to run concurrently.Value will be realised through commercialisation of the licensed medicine or an outright sale of the licence to a larger pharmaceutical company.